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Abstract 1 
Background. Atrial fibrillation (AF) catheter ablation is increasingly proposed for patients 2 
suffering from AF and concomitant heart failure (HF). However, the optimal ablation strategy 3 
remains controversial. We performed this study to assess the prevalence of pulmonary vein (PV) or 4 
linear lesion reconnection in HF patients undergoing repeated procedures. 5 
Methods and Results. At seven high-volume centres, 165 patients with HF underwent a repeat 6 
procedure after a first AF ablation including PV isolation alone (47 patients, group A) or PV 7 
isolation plus left atrial lines (118 patients, group B). Group A patients presented more often 8 
paroxysmal AF (p<0.001), less enlarged left atrium (p<0.001) and less left ventricular systolic 9 
dysfunction (p=0.031) compared to Group B, that more commonly had atypical atrial flutter 10 
(p<0.001). Forty-one (87%) patients in Group A and 69 (58%) in Group B presented at least one 11 
reconnected PV (p<0.001). Sixty-one (52%) patients in Group B presented at least one reconnected 12 
atrial line (left isthmus or roof). Patients without any reconnected PV (n=54, 33%) more frequently 13 
experienced persistent AF (p<0.001), had longer AF duration (p=0.047) and larger left atrial 14 
volume (p<0.001). Twenty-five patients (15%) with no PV and/or line reconnection did not 15 
significantly differ, concerning baseline characteristics, compared to those with at least one 16 
reconnected ablation site.  17 
Conclusion. As in the general AF population undergoing catheter ablation, PV reconnection is 18 
frequent in patients with HF and symptomatic recurrence. However, one third of patients presented 19 
arrhythmic recurrences even in the absence of PV reconnection, highlighting the importance of the 20 
underlying atrial substrate.  21 
 22 
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1. Introduction 1 
Atrial fibrillation (AF) catheter ablation is a proven safe and effective therapeutic option for patients 2 
suffering from AF and concomitant heart failure (HF) [1-2]. Recent randomized trials [3-5] and a 3 
large meta-analysis [6] consistently reported an improvement in systolic HF symptoms and left 4 
ventricular ejection function (LVEF) after AF ablation. However, freedom from AF after a single 5 
procedure is limited, and when long-term outcomes of 5 years or greater are examined, recurrences 6 
occur in the majority of patients [7]. As a consequent, many patients with systolic HF (about one 7 
third) require at least two procedures to effectively maintain long-term sinus rhythm (SR) [7].  8 
The optimal first line non pharmacological strategy to address AF in these patients remains 9 
controversial: previous studies supported, due to the complexity of the atrial substrate, left atrial 10 
linear ablation on top of pulmonary vein isolation (PVI) [8-10]. However, recent studies of AF 11 
ablation in general and surgical populations have failed to support the additive benefit of ablation 12 
beyond PVI [11-12]. In fact, aiming to investigate the singular role of PVI in AF ablation, a recent 13 
study reported, among a general population of patients undergoing repeated procedures for AF 14 
recurrence, a high prevalence of PV conduction recovery following the index PVI [13]. In this 15 
study, PV re-isolation alone was effective in subsequent SR maintenance, indirectly suggesting a 16 
durable role of PV triggers.  17 
AF ablation patients that have concurrent systolic HF may have arrhythmia driven not only by PV 18 
triggers, but pathological atrial substrate; the latter reflecting chronic exposure of the atrium to the 19 
underlying diastolic and systolic dysfunction [14-15]. Nonetheless, there are no data available 20 
concerning sites of recovery or reconduction following a first transcatheter ablation procedure. We 21 
therefore conducted the present study aiming to determine the incidence of PV reconnection or 22 
failure of other linear lesions in in a population of patients with HF undergoing repeated procedures 23 
for recurrent atrial arrhythmia following a first, failed, AF ablation procedure.  24 
 25 
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2. Methods 1 
The present multicentre study involved seven high-volume electrophysiological laboratories 2 
routinely performing AF transcatheter ablation in patients with a LVEF lower than 50%. All 3 
included patients had a history of drug-refractory, symptomatic, paroxysmal or persistent AF and a 4 
concomitant structural cardiomyopathy characterized by a LVEF < 50%, received a prior AF 5 
ablation procedure at the same Center (including PV isolation and when appropriate additional left 6 
or right atrial lesions), and were referred for at least one additional AF catheter ablation procedure, 7 
due to the occurrence of documented AF, atypical atrial flutter or atrial tachycardia symptomatic 8 
recurrences. Arrhythmic recurrences were defined as any episode of AF, atypical atrial flutter or 9 
atrial tachycardia lasting at least 2 minutes and documented through 12-leads ECG, Holter 10 
monitoring or implantable loop recorder. Referral for redo ablation was considered in patients 11 
experiencing arrhythmia-related symptoms, left ventricular function and/or functional class 12 
impairment related to the arrhythmic recurrences. Patients in whom procedural details concerning 13 
the index or the repeated procedure (e.g. PVI, linear lines, etc.) were not complete or validated were 14 
excluded. All patients provided written informed consent to the catheter ablation procedures. 15 
 16 
2.1. Recovery or reconduction assessment 17 
The number and sites of PV conduction recovery were recorded. Additionally, in case left atrial 18 
(LA) linear lesions (roof line, mitral isthmus line, posterior line) had been performed at the first 19 
procedure, the persistence of block lines tested by pacing manoeuvres, activation and voltage 20 
mapping were registered. 21 
The repeated procedures were then performed, according to each Center’s preference or protocols, 22 
using 4-mm tip irrigated radiofrequency catheters or cryoballoon. Based on single patients’ 23 
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characteristics and atrial substrate, additional lesions such as PV isolation, LA linear lines, or 1 
complex fractionated atrial electrograms (CFAE) were performed [16].  2 
 3 
2.2. Statistical analysis 4 
Continuous variables were reported as mean (standard deviation, SD) or median (range), and 5 
categorical variables as number (%). Continuous data were compared by one-way ANOVA test 6 
after normal distribution was confirmed, and, in a selection of cases, additionally analyzed as 7 
tertiles. Categorical variables were compared in cross-tabulation tables by Pearson’s chi-square test.   8 
Due to the potential bias resulting from the inclusion of atypical flutter/tachycardia recurrences, that 9 
may rely on different pathophysiological mechanisms than those driving AF, data was also analysed 10 
considering only AF recurrences. Aiming to test the independent correlation of the recorded 11 
parameters, variables reporting a significant correlation at univariate analysis (p value <0.05) were 12 
included in a multiple logistic regression analyses. The best subset models were run applying odds 13 
ratio (OR) likelihood scores. All tests of significance were two-tailed, and a p value <0.05 was 14 
considered statistical significant. All analyses were performed using SPSS 21.0. 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
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3. Results 1 
At seven high-volume centres, out of 719 patients, over a mean period of 3 years (2012-2015), the 2 
165 AF patients with concomitant HF undergoing a repeated transcatheter AF ablation were 3 
included (age 55±17 years; 83% males). Baseline characteristics are listed in Table 1. Sixty-four 4 
(39%) patients suffered from paroxysmal AF, with a mean AF history duration of 74±84 months. 5 
Echocardiographic parameters included a mean LA volume of 121±68 ml, and a mean LVEF 6 
41±8%. At the time of the index procedure, 47 (28%, Group A) patients underwent PVI alone, 7 
while 118 (72%, Group B) underwent additional LA linear lesions or CFAE ablation; in particular, 8 
in 104 patients a roof line and mitral isthmus line were performed, and 44 underwent CFAE 9 
ablation. Patients in Group A presented higher prevalence of paroxysmal AF (p<0.001), less 10 
severely enlarged LA volume (p<0.001), less LVEF dysfunction (p=0.031), shorter time to AF 11 
recurrence (p<0.001), and a higher prevalence of prior antiarrhythmic Ic class drugs treatment 12 
(p=0.019). In comparison, patients in Group B reported a higher prevalence of atypical atrial flutter 13 
recurrences, compared to Group A (p<0.001).  14 
Details concerning the second procedures are reported in Table 1. Briefly, 61 (37%) patients 15 
underwent repeated PVI alone, 61 (37%) underwent PVI and additional LA lesions while 43 (26%) 16 
underwent linear lesions or CFAE ablation; complication rate was 3.0%, without difference 17 
between Groups A and B (p=0.391). Forty-one (87%) patients in Group A and 69 (58%) in Group B 18 
presented at least one reconnected PV (p<0.001); no significant differences were detected among 19 
the prevalence of each of the four PV’s recurrence rate (Figure 1 and 2). Among patients in Group 20 
B, 61 (52%) and 55 (47%) presented, respectively, left isthmus and roof line reconnection across 21 
the line, and these patients underwent repeated linear ablation to achieve conduction block.  22 
Among the two groups, 54 (33%) patients presented without evidence of reconnected PVs (Table 23 
2); these patients were more often affected by persistent AF (p<0.001), had a longer AF duration 24 
(p=0.047), presented with more severely enlarged LA volumes (p<0.001), more often were treated 25 
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with extensive LA ablation at the initial procedure (p<0.001) including lines and CFAE, and were 1 
more commonly affected by atypical flutter (p<0.001). The complication rates did not differ 2 
between the two groups (p=0.688). 3 
Aiming to limit potential bias deriving from the inclusion of atypical flutter/tachycardia 4 
recurrences, that may rely on different pathophysiological mechanisms than those driving AF, an 5 
additional analysis was run stratifying by AF (n=100) or organized tachycardia (n=65) relapses. The 6 
presence of persistent vs. paroxysmal AF (p<0.001), of a larger LA volume (p=0.001), a lower 7 
LVEF (p=0.027), an ablation scheme including linear lesions (p=0.001) and CFAE ablation 8 
(p=0.002) related to arrhythmic recurrence despite the absence of documented PVs reconnection, 9 
also when considering AF recurrences only (Table 3 and Figure 3).  10 
At multiple logistic regression analyses, performed to assess the independent significance of each of 11 
the above mentioned parameters in relation to AF recurrences despite absence of PV reconnection, 12 
LA volume emerged as the only independently related parameter, as the III tertile of LA volume, 13 
above 120 ml, presented an OR of 5.09 (95% CI 1.19-26.19; p=0.048) (Table 4). On the other side, 14 
conduction recovery over atrial ablation lines was slightly more common within patients relapsing 15 
with an atrial tachycardia/atypical flutter: more in details, while the incidence of roof line 16 
reconnection did not differ (31 vs. 23%, p=0.267), the left isthmus line, recovered in 17% vs. 64% 17 
(p=0.013), in patients suffering AF or organized arrhythmias, respectively. 18 
Of note, 25 (15%) patients presented no PV and/or atrial line recovery at the time of the repeated 19 
procedure, despite the documented arrhythmia recurrences. Baseline characteristics of these patients 20 
were not significantly different, except for a trend towards longer AF duration (p=0.078) and lower 21 
LVEF (p=0.082) compared to the remaining population; patients without any reconnection site 22 
more frequently underwent CFAE ablation at the initial procedure (p=0.044) and presented with 23 
atypical flutter (p=0.003) compared to AF in the alternative group (Supplemental Table A). 24 
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Fifty (30%) of the 165 patients enrolled underwent a third procedure (Supplemental Table B and C). 1 
Among them, 18 (37%) experienced AF, while the majority, 32 (63%), suffered atypical atrial 2 
flutter (p=0.028). Fifteen of them had previously been approached by PVI alone, while 35 by 3 
extensive LA ablation. In the first group, 6 (40%) patients reported no reconnected PVs, while this 4 
percentage was higher (24, 70%) in the second; furthermore, in the latter the prevalence of left 5 
isthmus and roof line conduction recovery was 67% and 54%, respectively (supplemental Figure A 6 
and B). 7 
 8 
  9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
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4. Discussion 1 
The present work is the first multicentre study aiming to assess the durability of PVI and atrial 2 
linear ablation in a population of patients with systolic HF. In light of the latest European guidelines 3 
[2] recommending AF ablation in patients with HF (class IIa) to improve functional class and LVEF 4 
by breaking the vicious circle between AF and HF, knowledge on conduction recovery patterns is of 5 
extreme clinical relevance. Despite the heterogeneity of the population and of the ablation tools and 6 
protocols, given that the optimal approach for AF ablation in these patients is controversial, and the 7 
lack of clear published data on this population, the present findings are, in our opinion, significant 8 
and thought-provoking. In this population, and consistent with other studied populations, the rate of 9 
conduction recovery of at least one PV was high in patients that present for a repeated ablation: 10 
globally more than half of the previously isolated PVs were found to be reconnected at redo 11 
procedure. However, one third of patients undergoing repeated procedures for atrial arrhythmic 12 
recurrence had absence of PV reconnection, suggesting the importance of non-PV mechanisms in 13 
the AF pathogenesis, in particular within patients with a larger LA volume, lower LVEF that 14 
suffered persistent, long-history AF. These parameters, on top of all LA volume, should therefore 15 
candidate to identify patients at higher risk of AF recurrences, despite the persistence of PV 16 
isolation. In patients with HF, therefore, the PV’s role in AF genesis and maintenance seems less 17 
pivotal, highlighting the need to further treat external PV antral and the underlying atrial substrate.  18 
 19 
4.1. Reconnection sites and arrhythmic recurrences 20 
Concerning the first procedural approach, less than one third of patients underwent PVI alone, while 21 
the majority underwent a more extensive LA ablation. Baseline characteristics of the two groups 22 
were different: patients with persistent AF, longer AF history, lower LVEF and larger LA volume 23 
underwent more frequently an extensive LA ablation. This is in accordance with previous studies 24 
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suggesting, in these conditions, a more aggressive substrate modification strategy may be required 1 
in addition to PVI to provide long-term arrhythmia free benefit [9,17-18].  2 
Index procedure approach predicted arrhythmia outcomes in this cohort of systolic HF patients.  In 3 
those with PVI alone, AF recurrence alone was more common. In contrast, in patients that had 4 
extensive substrate modification recurrent atypical flutter rates were higher. Of note, almost half of 5 
the latter patients had recovered conduction along one or more of the previously performed lines, 6 
confirming the challenge of achieving a durable line of block [19] and the consequent 7 
proarrhythmic role of incomplete lesions [11].  8 
One third of all patients presented with no PV conduction recovery, suggesting, in patients with AF 9 
and concomitant HF, a relevant role for non-PV mechanisms that trigger and sustain arrhythmic 10 
recurrences, not only in case of organized atrial arrhythmias but also of AF recurrences. This 11 
prevalence is higher compared to a prior report that examined post-ablation recurrence rates in the 12 
general population [13], likely due to the more complex atrial substrate in patients with reduced 13 
LVEF. Persistent AF, larger LA volume and more depressed LVEF reflect more advanced atrial 14 
disease, in which AF can occur even in the absence or independently of PV triggers.  15 
The latter hypothesis is also supported by the larger prevalence of PV reconnection among the “PVI 16 
alone group” compared to “PVI + lines group”. The “PVI alone group” likely represents patients 17 
with less extensive atrial disease, in whom PV triggers still play a major role. The “PVI + lines 18 
group” includes, instead, patients with more advanced atrial disease, in whom PV triggers are less 19 
pivotal compared to the role exerted from reconnection of previous ablation lines or progression of 20 
the underlying atrial (extra-PV) disease. In fact, previous literature has already reported high PV 21 
reconnection rates even in patients free from arrhythmic recurrences [20]. 22 
Given the lack of clinical trials clearly testing the active role of PV reconnection in AF recurrences, 23 
and/or data deriving from positive controls, especially in the setting of patients with underlying 24 
structural disease and reduced LVEF, current practice should be based on the only available 25 
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observations. Based on the present findings, a severely dilated LA volume is, in our opinion, the 1 
strongest predictor of arrhythmia recurrences despite persistent PV isolation, suggesting that 2 
patients with severe LA enlargement (i.e. above 120-150 ml) should be treated by an alternative 3 
ablation approach at their index ablation procedure. Although among the general population, 4 
indirect support to this thesis derives from the recent GAP-AF trial [21]. This study demonstrated 5 
that complete is superior to incomplete circumferential PV isolation concerning 3-months AF 6 
ablation efficacy; however, this was not due to higher rates of persistent PV isolation. This finding 7 
surely suggests that more ablation is more effective than less ablation, but also highlights that the 8 
mechanisms of AF recurrences are not strictly linked to PV reconnection and that there, indeed, is a 9 
potential relevant role of non-PV mechanisms in AF recurrences also in the general population. 10 
Additionally, a recent report suggested that the altered substrate in HF patients may provide a role 11 
for non-PV mechanisms even in patients with paroxysmal AF [22]. This finding is consistent with 12 
the lower incidence of reconnected PVs among patients treated with PVI + lines compared to those 13 
treated with PVI alone: the first group, characterized by more advanced disease, most likely 14 
presents a higher burden of atrial fibrosis, that limits the role of PV triggers in supporting 15 
arrhythmic recurrences, and may, even more, result in a sort of fibrosis-induced “ablation” of the 16 
PVs trigger due to the progressive reduction of muscular sleeves. 17 
In further support of non-PV mechanisms in systolic HF patients, those who underwent a third 18 
ablation procedure, PV reconnection rates were even lower (44%) compared to that reported in the 19 
general population [13]. This subgroup was selected by failure of two prior ablations that targeted 20 
the PVs, and is likely a population with a more advanced atrial disease [23], in which PV ectopies 21 
are not pivotal, while the atrial substrate plays a dominant role in causing AF recurrence. However, 22 
44% of patients still experienced PV reconnection, which also highlights the challenges of obtaining 23 
durable PVI even with repeated attempts.  24 
 25 
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4.2. Absence of reconnection sites and arrhythmic recurrences  1 
About 15% of the patients referred for repeated procedures suffered arrhythmic recurrences without 2 
any reconnected PV and/or line. Unfortunately, none of the baseline characteristics permitted 3 
differentiation between these “non-responder” patients and the others, though there was a trend 4 
towards longer AF duration and lower LVEF. During the repeated procedure, these patients and 5 
those with passive residual PV reconnections were, in case of recurrent AF, frequently approached 6 
with additional CFAE ablation, felt to be involved in areas of micro-reentry and focal triggers 7 
resulting in atrial arrhythmia relapses [24-25]. Following AF conversion into atypical flutter or in 8 
case of primary recurrent atrial tachycardia, these extra-PV mechanisms or localized sources could 9 
be directly identified to underlie the recurrent arrhythmia mechanism and ablated with more 10 
selective approach. Indeed, this subgroup of patients (arrhythmia relapses despite isolated PVs and 11 
validated atrial linear blocks) may receive the greatest benefit from an atrial substrate modification 12 
approach, failed among unselected general populations [26-29].  13 
Indeed, in our opinion, by widening available knowledge, the present findings further support the 14 
usefulness of an extensive substrate modification for patients with advanced atrial disease, a 15 
frequent feature among patients with HF and severely reduced LVEF.  16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
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5. Limitations 1 
First, the retrospective non-randomized design does not permit to perform a standardized 2 
evaluation of the parameters analysed. Second, the inclusion of patients from different centres, 3 
along with different procedural tools and protocols, although being representative of the real-life 4 
picture of current clinical practice, may increase heterogeneity among the population studied. 5 
Third, the high prevalence of atypical flutter/tachycardia recurrences suggest that many patients 6 
suffered arrhythmic recurrences mainly due to the difficulties in achieving durable conduction 7 
block across ablation lines. However, even after considering AF recurrences alone, severe LA 8 
enlargement emerged as an independent predictor of AF recurrences despite durable PV isolation, 9 
identifying therefore a subgroup of HF patients that warrants extensive substrate modification for 10 
rhythm control already at index procedure. Indeed, the active role of PVs in arrhythmic 11 
recurrences cannot be confirmed, as the recording of focal activity from PV was not reported. 12 
Furthermore, studies that examine the role of durable PVI isolation on arrhythmia recurrence 13 
remain significantly limited by the finding that durable PVI is often no achieved. As such, until 14 
PVI are completely eliminated through durable electrical isolation, there role in arrhythmia genesis 15 
and maintenance cannot be excluded. Last, the relatively limited sample of patients included in the 16 
study may limit the statistical relevance. 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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6. Conclusion 1 
Based on the present findings, atrial substrate in HF patients appears more important than in the 2 
general AF population, and substrate modification may be required to reduce atrial arrhythmia 3 
recurrences. Severe LA enlargement, severely reduced LVEF and persistent/long standing AF are 4 
associated with reduced success of AF control with PVI alone. 5 
In this scenario, an alternative LA ablation approach is most probably needed to achieve effective 6 
rhythm control, especially among patients with severely enlarged LA. However, if additional 7 
ablation is incomplete or allows substrate for re-entry, then such ablation may be proarrhythmic. 8 
Nonetheless, the evidence of arrhythmic recurrences in absence of evident reconnection sites in this 9 
study, strongly highlights, at least within patients with AF and HF, the importance of substrate 10 
modification. In case future research will succeed in increasing knowledge concerning the role of 11 
alternative non-PV mechanisms and the interpretation of atrial substrate (e.g. drivers and/or rotors), 12 
this will surely improve the outcome of AF catheter ablation in patients at an advanced stage of the 13 
disease, as those with HF who most probably require a distinct, targeted ablation approach.  14 
 15 
 16 
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Table 1. Baseline characteristics of the study population according to index procedure. 1 
 Overall (n=165) Group A: PVI 
alone (n=47) 
Group B: PVI + 
lines (n=118) 
p-value 
Age, years (SD) 55 (17) 53 (22) 56 (15) 0.401 
Male sex, n (%) 137 (83%) 38 (81%) 99 (84%) 0.137 
Paroxysmal AF, n 
(%) 
64 (39%) 33 (70%) 32 (27%) <0.001 
Persistent AF, n (%) 43 (26%) 9 (19%) 33 (28%)  
Long-standing 
persistent AF, n (%) 
59 (36%) 5 (10%) 53 (45%)  
AF duration, months 
(SD) 
74 (84) 69 (68) 76 (91) 0.679 
Hypertension, n (%) 106 (64%) 33 (70%) 72 (61%) 0.343 
Diabetes mellitus, n 
(%) 
26 (16%) 8 (18%) 16 (14%) 0.730 
Previous stroke/TIA, 
n (%) 
18 (11%) 5 (11%) 13 (11%) 0.782 
CAD, n (%) 20 (12%) 6 (13%) 14 (12%) 0.989 
Hyperthyroidism, n 
(%) 
12 (7%) 2 (4%) 11 (9%) 0.093 
Amiodarone use, n 
(%) 
56 (34%) 14 (30%) 41 (35%) 0.499 
Ic class drug use, n 
(%) 
35 (21%) 16 (34%) 20 (17%) 0.019 
Beta-blockers, n (%) 104 (63%) 33 (70%) 72 (61%) 0.296 
21 
 
OAC, n (%) 145 (88%) 38 (81%) 106 (90%) <0.001 
LVEF, % (SD) 41 (8) 44 (7) 41 (8) 0.031 
LA volume, ml (SD) 121 (68) 56 (28) 152 (57) <0.001 
PVI alone, n (%) 47 (28%) 47 (100%) 0 - 
PVI + lines, n (%) 118 (72%) 0 118 (100%) - 
Left isthmus line, n 
(%) 
104 (62%) 0 104 (88%) - 
Roof line, n (%) 104 (62%) 0 104 (88%) - 
Posterior line, n (%) 21 (13%) 0 21 (18%) - 
CFAE, n (%) 44 (26%) 0 44 (42%) - 
Right isthmus 
ablation, n (%) 
97 (58) 9 (19%) 88 (76%) <0.001 
Complications, n 
(%) 
3 (2%) 1 (2%) 2 (3%) 0.541 
Time to recurrence, 
months (SD) 
12 (14) 8 (14) 9 (8) <0.001 
Paroxysmal AF 
recurrence, n (%) 
44 (27%) 30 (63%) 14 (12%) <0.001 
Persistent AF 
recurrence, n (%) 
56 (34%) 14 (30%) 42 (36%)  
Atypical flutter 
recurrence, n (%) 
65 (39%) 3 (7%) 62 (52%)  
Number of 
reconnected PVs, n 
(SD) 
1.9 (1.6) 3.1 (1.2) 1.5 (1.5) <0.001 
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Reconnected PVs 
- 0 
- 1 
- 2 
- 3 
-4 
 
54 (32) 
16 (9) 
30 (18) 
24 (14) 
46 (27) 
 
4 (8) 
1 (2) 
6 (13) 
11 (23) 
25 (54) 
 
49 (42) 
15 (13) 
19 (16) 
13 (11) 
21 (18) 
<0.001 
Repeated procedure characteristics 
PVI alone, n (%) 61 (37%) 31 (65%) 43 (36%) <0.001 
PVI + lines, n (%) 61 (37%) 14 (30%) 27 (23%)  
Lines/CAFE alone, 
n (%) 
43 (26%) 2 (5%) 48 (41%)  
Left isthmus line, n 
(%) 
74 (44%) 7 (15%) 67 (56%) <0.001 
De novo left isthmus 
line, n (%) 
7 (4%) 7 (15%) - - 
Roof line, n (%) 70 (42%) 14 (30%) 56 (47%) 0.042 
De novo roof line, n 
(%) 
14 (8%) 14 (30%) - - 
Posterior line, n (%) 23 (14%) 2 (4%) 21 (18%) 0.042 
CFAE ablation, n 
(%) 
33 (20%) 7 (15%) 26 (22%) 0.333 
Right isthmus 
ablation, n (%) 
42 (25%) 4 (9%) 38 (32%) 0.002 
Complications, n 
(%) 
5 (3.0%) 1 (2.1%) 4 (3.4%) 0.391 
23 
 
 1 
PVI: pulmonary vein isolation; AF: atrial fibrillation; TIA: transient ischaemic attack; CAD: 2 
coronary artery disease; OAC: oral anticoagulant; LVEF: left ventricular ejection fraction; LA: left 3 
atrium. CFAE: complex fractioned atrial electrograms. 4 
 5 
 6 
7 
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Table 2. Baseline population and procedural characteristics stratified according to the presence or 1 
absence of at least one PV conduction recovery detected at repeated procedure 2 
 PVs reconnection 
(n=111) 
Absence of PVs 
reconnection (n=54) 
p-value 
Age, years (SD) 54.9 (18) 55.8 (16) 0.767 
Male sex, n (%) 93 (84%) 44 (82%) 0.457 
Paroxysmal AF, n (%) 55 (50%) 8 (15%) <0.001 
Persistent AF, n (%) 28 (25%) 15 (28%)  
Long-standing persistent AF, 
n (%) 
28 (25%) 32 (59%)  
AF duration, months (SD) 62 (59) 95 (114) 0.047 
Hypertension, n (%) 62 (56%) 37 (69%) 0.357 
Diabetes mellitus, n (%) 16 (14%) 9 (17%) 0.960 
Previous stroke/TIA, n (%) 12 (11%) 6 (11%) 0.686 
CAD, n (%) 13 (12%) 7 (13%) 0.879 
Amiodarone use, n (%) 38 (34%) 18 (33%) 0.968 
Ic class drug use, n (%) 31 (28%) 4 (7%) 0.004 
Beta-blockers, n (%) 69 (62%) 35 (65%) 0.837 
OAC, n (%) 82 (74%) 52 (96%) 0.001 
LVEF, % (SD) 42.8 (8) 39.8 (7) 0.052 
LA volume, ml (SD) 95 (62) 159 (58) <0.001 
PVI alone, n (%) 41 (37%) 6 (11%) <0.001 
PVI + lines, n (%) 70 (63%) 48 (89%)  
Left isthmus line, n (%) 65 (59%) 39 (72%) 0.079 
25 
 
Roof line, n (%) 65 (59%) 40 (74%) 0.036 
Posterior line, n (%) 14 (13%) 20 (37%) 0.003 
CFAE ablation, n (%) 20 (18%) 32 (59%) <0.001 
Right isthmus ablation, n (%) 57 (51%) 41 (76%) 0.002 
Complications, n (%) 2 (1.8%) 1 (1.8%) 0.688 
Time to recurrence, months 
(SD) 
13 (14) 10 (14) 0.218 
Paroxysmal AF recurrence, n 
(%) 
40 (36%) 4 (7%) <0.001 
Persistent AF recurrence, n 
(%) 
40 (36%) 16 (30%)  
Atypical flutter recurrence, n 
(%) 
31 (28%) 34 (63%)  
 1 
PVI: pulmonary vein isolation; AF: atrial fibrillation; TIA: transient ischaemic attack;  CAD: 2 
coronary artery disease; OAC: oral anticoagulant; LVEF: left ventricular ejection fraction; LA: left 3 
atrium. CFAE: complex fractioned atrial electrograms. 4 
 5 
 6 
 7 
8 
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Table 3. Characteristics of patients experiencing paroxysmal/persistent AF recurrences stratified 1 
according to the presence or absence of at least one PV conduction recovery detected at repeated 2 
procedure. 3 
 Overall AF 
recurrences (n=100) 
PVs reconnection 
(n=80) 
Absence of PVs 
reconnection (n=20) 
p-value 
Paroxysmal AF, n (%) 52 (52) 51 (64%) 1 (5%) <0.001 
Persistent AF, n (%) 18 (18) 9 (11%) 9 (45%)  
Long-standing persistent 
AF, n (%) 
30 (30) 20 (25%) 10 (50%)  
AF duration, months (SD) 79 (85) 72 (63) 103 (134) 0.228 
LVEF, % (SD) 43.0 (8) 43.6 (8.1) 41.0 (6.4) 0.049 
LA volume, ml (SD) 93 (66) 75 (57) 146 (65) 0.001 
PVI alone, n (%) 49 (49) 47 (59%) 2 (10%) 0.001 
PVI + lines, n (%) 51 (51) 33 (41%) 18 (90%)  
Right isthmus ablation, n 
(%) 
38 (38) 26 (32%) 12 (60%) 0.065 
Complications, n (%) 1 (1) 1 (1.3%) 0 (0%) 0.657 
Time to recurrence, 
months (SD) 
13 (15) 16 (15) 9 (10) 0.016 
 4 
PV: pulmonary veins; PVI: pulmonary vein isolation; AF: atrial fibrillation; LVEF: left ventricular 5 
ejection fraction; LA: left atrium. CFAE: complex fractioned atrial electrograms.  6 
 7 
 8 
 9 
10 
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Table 4. Multivariate analysis on patients relapsing with AF only (n=100) assessing the 1 
independent correlation to recurrences despite absence of PV reconnection of those parameters 2 
significant at univariate analysis (p<0.05).  3 
 4 
 
OR 95% CI p-value 
 AF type, paroxysmal vs. persistent  0.772 0.171-3.494 0.737 
LA volume, III tertile 5.090 1.192-26.188 0.048 
LVEF, III tertile 1.078 0.351-3.307 0.896 
PVI alone vs. lines/CFAE 8.127 0.119-35,212 0.499 
 5 
OR: odds ratio. CI: confidence interval. PV: pulmonary veins; PVI: pulmonary vein isolation; AF: 6 
atrial fibrillation; LVEF: left ventricular ejection fraction; LA: left atrium. CFAE: complex 7 
fractioned atrial electrograms. 8 
 9 
10 
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Figure legends 1 
Figure 1. Pattern of PVs conduction recovery detected at repeated procedure (n=165 patients), 2 
stratified according to first ablation protocol. PV: pulmonary vein. LSPV: left superior pulmonary 3 
vein; LIPV: left inferior pulmonary vein; RSPV: right superior pulmonary vein; RIPV: right inferior 4 
pulmonary vein. 5 
 6 
Figure 2. Number of reconnected pulmonary veins or incomplete linear lesions documented at 7 
repeated procedure, according to index procedure. PVI: pulmonary vein isolation. CFAE: complex 8 
fractioned atrial electrograms. 9 
 10 
Figure 3. Different patterns of LVEF, stratified by tertiles (A), LA volume, stratified by tertiles (B), 11 
atrial fibrillation subtype (C) and catheter ablation protocol performed at index procedure (D) 12 
among patients respectively experiencing PVs reconnection or without PVs reconnection at redo 13 
procedure. LVEF: left ventricular ejectionfraction. LA: left atrial. AF: atrial fibrillation. 14 
 15 
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 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
30 
 
Figure 2 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
31 
 
Figure 3. 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
